Editorially independent content, supported with advertising
11.19.20
NRR’s miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. Khanani closes out the series with the case of a patient whose disease stopped responding after a decade of anti-VEGF therapy. Listen here to learn how he approached the case. This editorially independent podcast is supported with advertising.
03.24.22
Art of Drug Choice: Treating New Wet AMD PatientsArshad M. Khanani, MD, MA; Lejla Vajzovic, MD, and Joseph M. Coney, MD
03.17.22
Art of Drug Choice: Who Is Best Suited for Extended-duration Therapy?Arshad M. Khanani, MD, MA; Lejla Vajzovic, MD; and Joseph M. Coney, MD
03.03.22
Art of Drug Choice: The Latest Advances in Wet AMD TherapyArshad M. Khanani, MD, MA; Lejla Vajzovic, MD, and Joseph M. Coney, MD
09.10.21
The Art of Drug Choice: International Panel in Wet AMD: Safety DataArshad M. Khanani, MD; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; Peter Kertes, MD, FRCSC
09.01.21
The Art of Drug Choice: International Panel in Wet AMD: The PipelineArshad M. Khanani, MD; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; Peter Kertes, MD, FRCSC
08.20.21
The Art of Drug Choice: International Panel in Wet AMD: Phase 3 and Real-World Data to WatchArshad Khanani, MD, MA; Justus Garweg, MD; Seenu Hariprasad, MD; Peter Kertes, MD, FRCSC
08.06.21
The Art of Drug Choice: International Panel in Wet AMD: When and Why Switching Therapy Makes SenseArshad M. Khanani, MD, MA; Justus G. Garweg, MD; Seenu M. Hariprasad, MD; and Peter Kertes, MD, FRCSC
11.19.20
The Art of Drug Choice: Safety in Wet AMDArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
11.19.20
The Art of Drug Choice: Wet AMD PipelineArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA
11.19.20
The Art of Drug Choice: Phase 3 Trials in Wet AMDArshad M. Khanani, MD, MA; Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA